{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:00:59Z","timestamp":1794373259773,"version":"4.9.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1038\/s41575-023-00877-x","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T12:02:43Z","timestamp":1702296163000},"page":"78-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel interventions against alcohol-related liver disease"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1854-1924","authenticated-orcid":false,"given":"Maja","family":"Thiele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5305-2483","authenticated-orcid":false,"given":"Christophe","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"877_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","volume":"5","author":"GBD 2017 Cirrhosis Collaborators","year":"2020","unstructured":"GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5, 245\u2013266 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"877_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000279","volume":"7","author":"A Wester","year":"2023","unstructured":"Wester, A., Shang, Y., St\u00e5l, P. & Hagstr\u00f6m, H. Time trends in mortality and life expectancy in 22,658 patients hospitalized with alcohol-associated cirrhosis: a nationwide cohort study. Hepatol. Commun. 7, e0279 (2023).","journal-title":"Hepatol. Commun."},{"key":"877_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2021.7683","volume":"326","author":"AK Singal","year":"2021","unstructured":"Singal, A. K. & Mathurin, P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA 326, 165\u2013176 (2021).","journal-title":"JAMA"},{"key":"877_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen, T. H. et al. The EASL Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399, 61\u2013116 (2022).","journal-title":"Lancet"},{"key":"877_CR5","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/S0140-6736(23)00497-X","volume":"401","author":"GMA Wyper","year":"2023","unstructured":"Wyper, G. M. A. et al. Evaluating the impact of alcohol minimum unit pricing on deaths and hospitalisations in Scotland: a controlled interrupted time series study. Lancet 401, 1361\u20131370 (2023).","journal-title":"Lancet"},{"key":"877_CR6","first-page":"523","volume":"8","author":"M Israelsen","year":"2023","unstructured":"Israelsen, M. et al. Rifaximin-\u03b1 for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. Gastroenterol. Hepatol. 8, 523\u2013532 (2023).","journal-title":"Gastroenterol. Hepatol."},{"key":"877_CR7","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.cgh.2022.11.033","volume":"21","author":"BS Hofer","year":"2023","unstructured":"Hofer, B. S. et al. Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis. Clin. Gastroenterol. Hepatol. 21, 2308\u20132317 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"877_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jhep.2022.11.013","volume":"78","author":"A Louvet","year":"2023","unstructured":"Louvet, A. et al. Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort. J. Hepatol. 78, 501\u2013512 (2023).","journal-title":"J. Hepatol."},{"key":"877_CR9","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/hep.31984","volume":"74","author":"L Otero Sanchez","year":"2021","unstructured":"Otero Sanchez, L. et al. Clinical course and risk factors for infection in severe forms of alcohol-associated liver disease. Hepatology 74, 2714\u20132724 (2021).","journal-title":"Hepatology"},{"key":"877_CR10","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1001\/jama.2023.4902","volume":"329","author":"A Louvet","year":"2023","unstructured":"Louvet, A. et al. Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: a randomized clinical trial. JAMA 329, 1558\u20131566 (2023).","journal-title":"JAMA"}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-023-00877-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-023-00877-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-023-00877-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T14:03:59Z","timestamp":1706796239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-023-00877-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1038\/s41575-023-00877-x","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"assertion":[{"value":"11 December 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.T. reports speaker fees from Echosens, Siemens, Norgine, Tillotts, Takeda and Madrigal; advisory fees from GE Healthcare, Boehringer Ingelheim and GSK; is a co-founder and board member of Evido.health; and is funded by grants from the Novo Nordisk Foundation (DECIDE, NNF 20OC0059393) and Horizon2020 (GALAXY, grant number 668031; LiverScreen, grant number 847989; MicrobPredict, grant number 825694). C.M. reports speaker fees from Echosens, Julius Clinical, Gilead Sciences and Surrozen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}